Madrigal Pharmaceuticals Inc (MDGL)vsModerna Inc (MRNA)
MDGL
Madrigal Pharmaceuticals Inc
$534.49
+0.26%
HEALTHCARE · Cap: $12.34B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 74% more annual revenue ($2.23B vs $1.28B). MDGL leads profitability with a -25.3% profit margin vs -141.4%. MDGL earns a higher WallStSmart Score of 31/100 (F).
MDGL
Avoid31
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MDGL.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 71.2% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Weak financial health signals
Trading at 23.6x book value
ROE of -62.1% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MDGL
The strongest argument for MDGL centers on Revenue Growth. Revenue growth of 71.2% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MDGL
The primary concerns for MDGL are EPS Growth, Piotroski F-Score, Price/Book.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MDGL profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MDGL is growing revenue faster at 71.2% — sustainability is the question.
MDGL generates stronger free cash flow (19M), providing more financial flexibility.
Bottom Line
MDGL scores higher overall (31/100 vs 21/100) and 71.2% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Madrigal Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?